Thomas Powles, MD, MBBS, MRCP

Articles

Understanding Unprecedented Data in Genitourinary Cancers From ESMO 2023: Dr Powles

October 20th 2023

OncLive® will be LIVE with OncLive® News Network: On Location at the 2023 ESMO Congress. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.

Key Takeaways on the Management of Metastatic Urothelial Carcinoma

January 25th 2022

Clinical pearls of advice regarding the optimal management of metastatic urothelial carcinoma in today’s treatment landscape.

Metastatic Urothelial Carcinoma: Second-Line Therapy and Beyond

January 25th 2022

Expert perspectives on novel treatment approaches being investigated in the second-line setting of metastatic urothelial carcinoma and beyond.

Practical Advice on Use of Maintenance Therapy in mUC

January 18th 2022

Practical advice on maintenance therapy in metastatic urothelial carcinoma, covering patient education, duration of therapy, and clinical guidelines.

Metastatic Urothelial Carcinoma: Interpreting JAVELIN Bladder 100

January 18th 2022

A review of the JAVELIN Bladder 100 trial, which evaluated avelumab maintenance therapy following frontline chemotherapy in metastatic urothelial carcinoma.

Impact of Maintenance Therapy on Metastatic Urothelial Carcinoma

January 11th 2022

The overall impact that maintenance therapy has had on patient outcomes in advanced or metastatic urothelial carcinoma.

Dr. Powles on Maintenance Avelumab in Urothelial Carcinoma

May 29th 2020

Thomas Powles, MD, MBBS, MRCP, discusses the utility of maintenance avelumab in the phase 3 JAVELIN Bladder 100 study in advanced urothelial carcinoma.

Dr. Powles on the 42-Month Follow-Up Data From the CheckMate-214 Trial in RCC

May 2nd 2020

Thomas Powles, MD, MBBS, MRCP, director, Barts Cancer Institute, discusses the 42-month follow-up data from the phase 3 CheckMate-214 trial in advanced renal cell carcinoma (RCC).

Dr. Powles on the Mission of the Uromigos Twitter Group

February 29th 2020

Thomas Powles, MD, MBBS, MRCP, discusses the mission and goals for the Uromigos Twitter group.

Dr. Powles on Design and Findings of the BISCAY Trial in Platinum-Refractory Urothelial Cancer

October 31st 2019

Thomas Powles, MD, MBBS, MRCP, professor, Genitourinary Oncology, lead for Solid Tumour Research, and director, Barts Cancer Institute, discusses the design and findings of the phase Ib BISCAY trial in platinum-refractory urothelial cancer.

Dr. Powles on Monitoring Immunotherapy Effects in Patients with RCC

July 13th 2019

Thomas Powles, MBBS, MRCP, MD, discusses the importance of accurately assessing the toxicity profiles of immunotherapies for renal cell carcinoma.

Dr. Powles on PD-L1 as a Biomarker in RCC

May 24th 2019

Thomas Powles, MD, MBBS, MRCP, professor, Genitourinary Oncology, lead for Solid Tumour Research, and director, Barts Cancer Institute, discusses the use of PD-L1 as a biomarker in renal cell carcinoma (RCC).